ArticleBMC chemistry2025
Application of cosolvency and cocrystallization approach to enhance acyclovir solubility.
Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Acyclovir (ACY) is a commonly used antiviral drug with limited aqueous solubility and poor permeability. It is administered via oral and intravenous routes. The aim of this work is to employ cocrystallization and cosolvency method to improve the solubility of orally administered dosage forms, including tablet and oral solution. Cocrystallization is carried out through the solvent evaporation method using different types of coformers including formic acid (FA), tartaric acid (TA), and ascorbic acid (AA). The physical states of the obtained samples were characterized by differential scanning calorimeter (DSC), X-ray diffraction (XRD), and Fourier transform infrared spectroscopy (FT-IR). The solubility of the developed samples were evaluated and compared with those of the parent drug. DSC and XRD findings indicate that ACY-AA and ACY-TA may be classified as cocrystals. Physicochemical characterization of ACY-FA did not demonstrate any change with respect to the parent drug. ACY-AA had the highest increase in drug solubility and created almost 3 folds enhancement. In another approach, cosolvency was employed to study the solubilization enhancement of 6 different binary solvent mixtures at 298.15 K. PEG 400 + water at 0.5:0.5 demonstrated a twofold enhancement in drug solubility. Both cocrystallization and cosolvency method seem effective in enhancing drug solubility and have the potential to be employed for the development of oral drug delivery systems including tablets and oral suspensions. The findings of this work suggest that ACY solubility can be enhanced by proper choice of the coformer and cosolvent. The result of this finding is beneficial for the development of acyclovir dosage forms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.